Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

156795

registered interest
date	19/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Chemicals: Safety
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will review the safety of the anti-bacterial agent Tricolsan; if he will place in the Library copies of reports his Department has received on the safety of this chemical in the last 12 months; and if he will make a statement.
tabling member constituency	West Bromwich East
tabling member printed	Mr Tom Watson
uin	215165
answer	answer is ministerial correction date of answer 24/11/2014 answer text <p>Triclosan is an antimicrobial agent that is present as an active ingredient in some pharmaceutical products, such as antiseptic skin solutions and medicinal toothpastes. As with all medicinal products, the Medicines and Healthcare products Regulatory Agency (MHRA) keeps the safety of triclosan-containing pharmaceuticals under continual review. The view of the MHRA is that the balance of risks and benefits of such products continues to be favourable. The MHRA is unaware of any new data relevant to humans to alter this view.</p><p> </p><p> </p><p> </p><p>Triclosan has also been used for more than 35 years in a wide range of consumer products for its antiseptic, disinfectant and preservative properties. This includes some soaps, cosmetics, detergents, shampoos, toothpastes and mouth washes.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 24/11/2014 17:38:14 answering member 4020 label Biography information for George Freeman
tabling member	1463 label Biography information for Lord Watson of Wyre Forest

143398

registered interest
date	07/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will issue a direction under Regulation 7 of the National Institue for Health and Care Excellence (NICE) (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 to exempt clinical commissioning groups from the requirement to comply with NICE Technology Assessment Guidance TA155, in order that NHS commissioners can make their own decision on whether to issue the drug Avastin and Lucentis.
tabling member constituency	West Bromwich East
tabling member printed	Mr Tom Watson
uin	213834
answer	answer is ministerial correction date of answer 17/11/2014 answer text <p>We have no such plans. The Government believes that drugs and treatments that are established as clinically and cost effective should be available to patients. The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance on Lucentis (ranibizumab) and Macugen (pegaptanib) for the treatment of age-related macular degeneration (TA155) that recommends Lucentis as a clinically and cost effective use of National Health Service resources for the treatment of patients with wet age-related macular degeneration meeting specific clinical criteria.</p><p> </p><p> </p><p> </p><p>Under Regulation 7, commissioners are legally required to make funding available so that clinicians can prescribe treatments recommended in NICE technology appraisal guidance to patients. This does not prevent commissioners from supporting the use of additional treatment options if they believe they would be of benefit to their local population.</p><p> </p><p> </p><p> </p><p>Avastin (bevacizumab) is not licensed for use in the treatment of wet age-related macular degeneration. Clinicians are able to prescribe drugs outside their marketing authorisation where they believe it is clinical appropriate, based on an assessment of their patient’s individual clinical circumstances.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 17/11/2014 11:14:36 answering member 4020 label Biography information for George Freeman
tabling member	1463 label Biography information for Lord Watson of Wyre Forest